Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4:16:1541005.
doi: 10.3389/fphar.2025.1541005. eCollection 2025.

Post-marketing safety re-evaluation of placental peptide injection in China: a large-scale multicenter real-world study

Liguang Duan #  1 , Feiyue An #  1 , Chen Tian  1 , Wen Yan  1 , Jie Chen  2 , Hongyin Zhang  3 , Xiaoguang Liu  4 , Lingjiao Wang  5 , Zhuo Zhang  1 , Binliang Tong  1 , Chunhua Zhou  5
Affiliations

Post-marketing safety re-evaluation of placental peptide injection in China: a large-scale multicenter real-world study

Liguang Duan et al. Front Pharmacol. .

Abstract

Purpose: This study conducted a post-marketing safety re-evaluation of placental polypeptide injections in China to support updates to drug guidelines, pharmacovigilance efforts, and rational clinical use, facilitating its inclusion in essential drug lists and medical insurance coverage.

Methods: A hospital-based centralized monitoring system tracked 3,000 patients receiving placental polypeptide injections across three medical institutions. Adverse drug reactions (ADRs) and adverse drug events (AEs) were systematically collected and analyzed.

Results: The mean patient age was 49.65 years, with 96.47% being over 18 years of age. A single dose exceeding 4 mL was administered in 98.34% of the cases, with a median treatment duration of 7 days. Concomitant medication use was high (injectable, 98.43%; non-injectable, 75.43%). One case of vertigo was reported as an ADR in a patient aged >60 years who had melanoma.

Conclusion: The ADR rate was 0.03%, confirming the favorable safety profile of placental polypeptide injection. These findings support its safe clinical use and can inform future regulatory and policy decisions.

Keywords: adverse drug reactions; centralized hospital monitoring method; placental peptide injection; post-marketing safety re-evaluation; real-world study.

PubMed Disclaimer

Conflict of interest statement

Author XL was employed by Beijing Dehuijia Pharmaceutical Technology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart of data collection.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abd-Allah S. H., El-Shal A. S., Shalaby S. M., Abd-Elbary E., Mazen N. F., Abdel Kader R. R. (2015). The role of placenta‐derived mesenchymal stem cells in healing of induced full‐thickness skin wound in a mouse model. Iubmb Life 67 (9), 701–709. 10.1002/iub.1427 - DOI - PubMed
    1. Bonamici S. (2024). Text - H.R.34 - 114th congress (2015-2016): 21st Century Cures Act. Available at: https://www.congress.gov/bill/114th-congress/house-bill/34 (Accessed December 01, 2024).
    1. Can W., Qing-Ping S., Feng D., Jiang X. D., Tang W., Yu M. L., et al. (2018). Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations. Drug Des. Dev. Ther. 12, 757–767. 10.2147/DDDT.S156000 - DOI - PMC - PubMed
    1. Chen X., Yang Y., Wang C., Liu H. (2022). Quality and safety risk analysis of thymidin preparation. Xibei yaoxue zazhi (01), 156–159. 10.3969/j.issn.1004-2407.2022.01.030 - DOI
    1. Chunhe Z., Fuxiang G., Yun X., Qiangmin B., Ziyan H., Bin S., et al. (2021). Re-evaluation of the clinical efficacy of Shu Mitong Capsules in the treatment of chronic prostatitis with damp-heat and blood stasis syndrome based on multicenter real-world studies. Chin. J. Traditional Chin. Med. (01), 544–548.

LinkOut - more resources